Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

EW vs STE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EW Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

EW Overall Winner 6-Pillar Tally: EW 4 – 2 STE Matrix Metrics: EW 7 – 3 STE

As of Nov 16, 2026, Edwards Lifesciences Corp (EW) is the stronger overall head-to-head candidate over STERIS plc (STE) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). EW carries a Unified Composite Score of 31.5/100 (SELL) at $106.66 (31.6x Forward P/E, 28.8% operating margin), whereas STE carries 28.1/100 (SELL) at $263.07 (23.9x Forward P/E, 19.2% operating margin).

  • Defensive Composite Rating Caution: Although EW compares more favorably head-to-head, both EW (31.5/100 SELL) and STE (28.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EW vs STE
EW NYSE Head-to-Head Winner
Edwards Lifesciences Corp
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$106.66
-0.46% 1D
Market Cap $60.8B
TTM Revenue $6.67B
Forward P/E 31.6x
Beta / 30D Vol 0.44β · 24% Vol
Unified Composite Score
31.5 / 100 SELL
Tech 50.0 Fund 29.0 Flow 51.0 Mom 44.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.7% over 20 days), RSI 79
RSI-14: 79.4 · SMA20: $97.03 · SMA50: $90.77
STE NYSE
STERIS plc
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$263.07
-0.47% 1D
Market Cap $24.6B
TTM Revenue $6.17B
Forward P/E 23.9x
Beta / 30D Vol 0.20β · 37% Vol
Unified Composite Score
28.1 / 100 SELL
Tech 50.0 Fund 33.0 Flow 56.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 76
RSI-14: 75.8 · SMA20: $241.47 · SMA50: $224.07

6-Pillar Scorecard Institutional Category Breakdown (EW 4 – 2 STE)

Columns: Metric · EW · STE
1. Valuation Multiples STE
Forward P/E 31.6x 23.9x
Trailing P/E 61.5x 30.4x
PEG Ratio 2.33x 2.50x
EV / Revenue 8.8x 4.2x
2. Growth & Scale EW
Revenue Growth (YoY) +10.5% +8.8%
Earnings Growth (YoY) +6.7% +12.9%
TTM Revenue (USD) $6.67B $6.17B
Market Cap $60.8B $24.6B
3. Profitability & Quality EW
Gross Margin 78.0% 44.3%
Operating Margin 28.8% 19.2%
Net Profit Margin 15.3% 13.4%
Return on Equity (ROE) 9.3% 11.6%
4. Balance Sheet & Cash Flow EW
Cash Generation (TTM) $1.42B $937M
Cash Flow Margin 21.3% 15.2%
Net Cash / Leverage $2.41B Net Cash $1.52B Net Debt (0.28x D/E)
Dividend Yield None (0.00%) 1.01%
5. Options & Positioning STE
Options Structure Phase UNCLASSIFIED SURGE
Current IV / %ile 24.6% (34th %ile) 32.2% (7th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup ACCUMULATION · Markup
6. R&D & Supply-Chain Moat EW
OpEx & R&D Intensity 49.2% of Rev ($3.28B) 25.1% of Rev ($1.55B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Scale & Operating Efficiency Moat
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EW (7) vs STE (3)
Institutional Metric EW STE Criterion Row Edge
Market Capitalization
Scale
$60.8B $24.6B Larger Scale EW
Trailing P/E Ratio
Valuation
61.5x 30.4x Lower Multiple STE
Forward P/E Ratio
Valuation
31.6x 23.9x Lower Multiple STE
Revenue Growth (YoY)
Growth
+10.5% +8.8% Higher Growth EW
Operating Margin (TTM)
Profitability
28.8% 19.2% Higher Margin EW
Net Profit Margin
Profitability
15.3% 13.4% Higher Margin EW
Return on Equity (ROE)
Capital Efficiency
9.3% 11.6% Higher ROE STE
52-Week Range Position
Momentum
96% ($75–$108) 91% ($195–$269) Stronger Trend EW
Beta / 30D Volatility
Risk Regime
0.44β · 24% Vol 0.20β · 37% Vol Lower Realized Risk EW
Unified Institutional Score
Composite Signal
31.5 / 100 (SELL) 28.1 / 100 (SELL) Higher Composite EW
Trailing 12M Revenue (USD)
Operating Scale
$6.67B $6.17B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
78.0% 44.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.33x PEG · 8.8x EV/Rev 2.50x PEG · 4.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.42B ($2.41B Net Cash) $937M ($1.52B Net Debt (0.28x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EW +5.01 pp
EW: +23.16% · STE: +18.15%
3M Horizon EW +4.03 pp
EW: +17.23% · STE: +13.2%
6M Horizon EW +5.87 pp
EW: +29.45% · STE: +23.58%
1Y Horizon EW +22.85 pp
EW: +23.86% · STE: +1.01%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period EW Revenue STE Revenue EW Op. Margin STE Op. Margin Margin Leader
FY2019 $4.35B $2.78B 26.4% 14.8% EW
FY2020 $4.39B $3.03B 20.5% 17.7% EW
FY2021 $5.23B $3.11B 32.3% 17.6% EW
FY2022 $4.46B $4.22B 33.6% 11.3% EW
FY2023 $5.01B $4.54B 26.1% 17.4% EW
FY2024 $5.44B $5.14B 25.3% 16.3% EW
FY2025 $6.07B $5.46B 20.8% 15.9% EW
FY2026 N/A $5.94B N/A 18.6% STE

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EW UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 24.6%
IV Percentile 34th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EW Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
STE SURGE
5d in phase · OBV ACCUMULATION
Current IV 32.2%
IV Percentile 7th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact STE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EW Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $60.8B market capitalization and 28.8% operating margin.
OpEx & R&D Reinvestment 49.2% of Rev ($3.28B)
90D Engineering Disclosures 0 Published
STE Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $24.6B market capitalization and 19.2% operating margin.
OpEx & R&D Reinvestment 25.1% of Rev ($1.55B)
90D Engineering Disclosures 0 Published

Investor FAQ EW vs STE Key Questions & Quantitative Answers

As of Nov 16, 2026, Edwards Lifesciences Corp (EW) is the stronger overall head-to-head candidate over STERIS plc (STE) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). EW carries a Unified Composite Score of 31.5/100 (SELL) at $106.66 (31.6x Forward P/E, 28.8% operating margin), whereas STE carries 28.1/100 (SELL) at $263.07 (23.9x Forward P/E, 19.2% operating margin). Defensive Composite Rating Caution: Although EW compares more favorably head-to-head, both EW (31.5/100 SELL) and STE (28.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

EW leads the Growth & Scale pillar: EW posts +10.5% YoY revenue growth and +6.7% YoY earnings growth on $6.67B TTM revenue (78.0% gross margin, 28.8% operating margin), compared with STE at +8.8% YoY revenue growth and +12.9% YoY earnings growth on $6.17B TTM revenue (44.3% gross margin, 19.2% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), EW cumulative revenue shifted +39.5% while STE shifted +113.7%. In operating R&D and SG&A reinvestment, EW deploys 49.2% of Rev ($3.28B) (0 90-day corporate R&D disclosures) versus 25.1% of Rev ($1.55B) (0 disclosures) for STE.

STE screens cheaper on headline valuation multiples. EW trades at 31.6x Forward P/E, 61.5x Trailing P/E, 2.33x PEG, and 8.8x EV/Revenue (21.3% FCF margin), whereas STE trades at 23.9x Forward P/E, 30.4x Trailing P/E, 2.50x PEG, and 4.2x EV/Revenue (15.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EW (9.3% ROE) versus STE (11.6% ROE) capital efficiency.

In options market volatility and institutional positioning, EW carries 24.6% implied volatility (34th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.44β · 24% Vol realized risk). By comparison, STE carries 32.2% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (0.20β · 37% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.